(NASDAQ:HGEN) shares are trading higher on positive financial results. Biotechnology is still a hot sector.

(NASDAQ:HGEN) shares are trading higher on positive financial results. Biotechnology is still a hot sector.

Humanigen Reports First Quarter 2022 Financial Results

SHORT HILLS, N.J.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab (LENZ), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

Read the entire artilcle: https://www.businesswire.com/news/home/20220505005996/en/Humanigen-Reports-First-Quarter-2022-Financial-Results

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.